Market Cap 447.62B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 24.86
Forward PE 17.03
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 9,758,976
Avg Vol 7,227,618
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 100%
Beta 0.32
Analysts Strong Sell
Price Target $250.97

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 8:13 PM
$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 7:54 PM
$SLS $GILD $ABBV What's really F'd Up Here - is the real investors who've loaded in here - Know - SLS Could Announce a Sale of SLS009 - the Secondary Asset - for $7B and noone would blink an eye. - just the secondary asset, SLS009 is worth at least $5 to $7B - $25 -$30 per share, right now. SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B... SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B... SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B...
0 · Reply
BarbaraSmith247
BarbaraSmith247 Jun. 29 at 7:50 PM
$ABBV trading around 255.30 today. Seeing some action on the pipeline front with trial milestones and regulatory opinions, which is keeping the sentiment constructive. Still, not looking to force a trade at these levels. Patience is the play.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 7:40 PM
$SLS $ABBV $SLS https://pmc.ncbi.nlm.nih.gov/articles/PMC10123586/#Sec7 iykyk / 80th EVENT PR is now Imminent.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 7:33 PM
$SLS $ABBV Share Price will Continue climbing until it Absolutely Launches. -- BAT FAILED 4 Recent AML Trials, Dr's Treating Actual SLS P3 Patients are on Record Stating BAT is Toxic, MOS is Dismal, extremely poor and they 'strongly believe Gps will reach the primary endpoint" - and 'revolutionize AML Remission maintenance'. Most who know are fairly Sure GPs is Golden, (if you don't know) The only real question is - What is Gps Worth? Cco Published Minimum Estimated Pricing $280K Rev P/p Y1 12,500 AML CR2 Patients Each Year 40,000 AML CR1 Patients Each Year +100,000 AML Patients Currently in Remission Who'll Immediately Benefit from GPs - right out of the GATE - Compounded Revenue / Infinite Dosing / - WT1 97% of ALL AML Patients.
0 · Reply
PeterRaslow
PeterRaslow Jun. 29 at 7:00 PM
$SLS with $ABBV not releasing the maintenance data for Viola studies this is my biggest Green Flag for a win take that to the bank
1 · Reply
WallStreetBulll
WallStreetBulll Jun. 29 at 6:36 PM
Market sentiment for $ABBV is bullish, with the stock trading at $255.40. Investors are noting a 9-month base breakout, suggesting potential for sustained momentum.
0 · Reply
liamsniperalert
liamsniperalert Jun. 29 at 4:31 PM
$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.75 772% GAINER! 🏆🗻
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 3:42 PM
$SLS $ABBV Does Every One know - Aza+VEN, BAT - Best Available Treatment for SLS P3 Control Arm Patients Recently Failed 4 large AML Trials conducted by ABBV? - Including FAILING 3 For AML Remission Maintenance? VIALE-M Phase 3 Trial for CR1 Maintenance FAILED VIALE-T Phase 3 Trial For post Transplant Maintenance Failed Large Phase 2 Reduced Intensity all Oral Failed Verona Phase 3 HR MDS/AML Precursor Failed -- AND -- We have 3 Dr's treating Actual SLS Phase 3 Patients on the Record Stating BAT is Toxic, MOS is 'Not Durable', 'Extremely poor", 'just 6-8 months 5-7 months' ---AND " I strongly believe Gps will reach the primary Endpoint "... It is not Complicated.
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:59 PM
$ABBV MUCH LOVE❤️
0 · Reply
Latest News on ABBV
AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 3 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call


AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 5 days ago

AbbVie's $11 Billion Immunology Bet

APGE


Apogee Therapeutics moved to No Rating at BofA

2026-06-23T11:29:50.000Z - 6 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE


AbbVie price target raised to $273 from $265 at Canaccord

2026-06-23T11:04:51.000Z - 6 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE


AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:24:35.000Z - 6 days ago

AbbVie announces European Commission approval for Skyrizi


AbbVie announces European Commission approval of Maviret

2026-06-23T10:00:54.000Z - 6 days ago

AbbVie announces European Commission approval of Maviret


AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 7 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE


AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Transcript: M&A announcement


AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Slides: M&A announcement


AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 7 days ago

AbbVie Press release: M&A announcement


AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 7 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE


AbbVie to acquire Apogee Therapeutics for $10.9B in cash

2026-06-22T11:15:52.000Z - 7 days ago

AbbVie to acquire Apogee Therapeutics for $10.9B in cash

APGE


AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 7 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE


AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 11 days ago

AbbVie Declares Quarterly Dividend


US FDA approves AbbVie's rare blood cancer drug

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug


AbbVie Transcript: AGM 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026


AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026


AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026


AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026


AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth


AbbVie Reports First-Quarter 2026 Financial Results

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results


US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment


55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 8:13 PM
$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 7:54 PM
$SLS $GILD $ABBV What's really F'd Up Here - is the real investors who've loaded in here - Know - SLS Could Announce a Sale of SLS009 - the Secondary Asset - for $7B and noone would blink an eye. - just the secondary asset, SLS009 is worth at least $5 to $7B - $25 -$30 per share, right now. SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B... SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B... SLS009 Phase 2 B AML-MR Data Published at ASH is better than Ph1B Magrolimab AML-MR Data Published at ASH that got bought for $4.9B...
0 · Reply
BarbaraSmith247
BarbaraSmith247 Jun. 29 at 7:50 PM
$ABBV trading around 255.30 today. Seeing some action on the pipeline front with trial milestones and regulatory opinions, which is keeping the sentiment constructive. Still, not looking to force a trade at these levels. Patience is the play.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 7:40 PM
$SLS $ABBV $SLS https://pmc.ncbi.nlm.nih.gov/articles/PMC10123586/#Sec7 iykyk / 80th EVENT PR is now Imminent.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 7:33 PM
$SLS $ABBV Share Price will Continue climbing until it Absolutely Launches. -- BAT FAILED 4 Recent AML Trials, Dr's Treating Actual SLS P3 Patients are on Record Stating BAT is Toxic, MOS is Dismal, extremely poor and they 'strongly believe Gps will reach the primary endpoint" - and 'revolutionize AML Remission maintenance'. Most who know are fairly Sure GPs is Golden, (if you don't know) The only real question is - What is Gps Worth? Cco Published Minimum Estimated Pricing $280K Rev P/p Y1 12,500 AML CR2 Patients Each Year 40,000 AML CR1 Patients Each Year +100,000 AML Patients Currently in Remission Who'll Immediately Benefit from GPs - right out of the GATE - Compounded Revenue / Infinite Dosing / - WT1 97% of ALL AML Patients.
0 · Reply
PeterRaslow
PeterRaslow Jun. 29 at 7:00 PM
$SLS with $ABBV not releasing the maintenance data for Viola studies this is my biggest Green Flag for a win take that to the bank
1 · Reply
WallStreetBulll
WallStreetBulll Jun. 29 at 6:36 PM
Market sentiment for $ABBV is bullish, with the stock trading at $255.40. Investors are noting a 9-month base breakout, suggesting potential for sustained momentum.
0 · Reply
liamsniperalert
liamsniperalert Jun. 29 at 4:31 PM
$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.75 772% GAINER! 🏆🗻
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 29 at 3:42 PM
$SLS $ABBV Does Every One know - Aza+VEN, BAT - Best Available Treatment for SLS P3 Control Arm Patients Recently Failed 4 large AML Trials conducted by ABBV? - Including FAILING 3 For AML Remission Maintenance? VIALE-M Phase 3 Trial for CR1 Maintenance FAILED VIALE-T Phase 3 Trial For post Transplant Maintenance Failed Large Phase 2 Reduced Intensity all Oral Failed Verona Phase 3 HR MDS/AML Precursor Failed -- AND -- We have 3 Dr's treating Actual SLS Phase 3 Patients on the Record Stating BAT is Toxic, MOS is 'Not Durable', 'Extremely poor", 'just 6-8 months 5-7 months' ---AND " I strongly believe Gps will reach the primary Endpoint "... It is not Complicated.
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:59 PM
$ABBV MUCH LOVE❤️
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:57 PM
$ABBV 🌊 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.30 🤑 667% GAINER! ☢️ LIKE THIS POST AND TURN MY POST NOTIFICATIONS ON TO JUMP ONBOARD! ☢️
0 · Reply
StockpeakHQ_1
StockpeakHQ_1 Jun. 29 at 2:56 PM
$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.30 667% GAINER!
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 2:35 PM
Telegram channel: https://t.me/BlockWave10 $ABBV You can call me the GOAT if you want. 😂🫶🏻 Heaven knows I’ll keep doing my part. Keep missing these opportunities, and you’ll keep missing out on making some serious profit.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:28 PM
$ABBV $PFE $RVMD $SLS 10 Million Volume in first full hours of trading. Word of a CURATIVE cancer platform that can tackle 20+ WT1 cancers GPS is spreading on Wall Street just a few blocks away from Sellas Headquarters in N.Y ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:21 PM
$ABBV $PFE $RVMD $SLS 0 Shares Available 👇 going to in to the biggest Catalyst in Sellas Corporate history with 63 Million short shares trapped. 👇 ✌️🙏❤️‍🩹
0 · Reply
Snipertradesexpert
Snipertradesexpert Jun. 29 at 2:06 PM
$ABBV Take a look🥂
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:01 PM
$ABBV $PFE $RVMD $SLS 🤩 Over 6.4 million Volume in first half hour up over 15%. I expect a T 1 halt before the Biggest Catalyst in Sellas Corporate history GPS Regal Pivotal Registrational phase 3 data= $120.00+ BO= $240.00+ Bidding War= $280.00+ ✌️🙏❤️‍🩹
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 1:49 PM
$ABBV $PFE $RVMD $SLS Potential T1 halt before next Catalyst. Traders and Repositioners will be left on the sidelines! SLS #1 Trending on Stocktwits WHY IT'S TRENDING SELLAS Life Sciences is surging as investors anticipate pivotal phase 3 clinical trial results, fueled by a high-pressure short squeeze environment and heavy institutional interest in its potential oncology breakthroughs. Community sentiment is overwhelmingly bullish, with active discussions focusing on the high cost to borrow shares, the scarcity of available short positions, and expectations for a major corporate catalyst. ✌️🙏❤️‍🩹
0 · Reply
ApexEquityVault
ApexEquityVault Jun. 29 at 1:40 PM
OH MY GOD!!!!!! I JUST MADE $19,000+ ON $ABBV I DO NOT MISS (NFA)
0 · Reply
Blockwave1
Blockwave1 Jun. 29 at 1:37 PM
I JUST MADE $19,000+ ON $ABBV I DO NOT MISS ON MY HIGH CONFIDENCES!!!!!!
0 · Reply
StockpeakHQ_1
StockpeakHQ_1 Jun. 29 at 1:36 PM
$ABBV $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $2.50 481% GAINER!
0 · Reply
Snipertradesexpert
Snipertradesexpert Jun. 29 at 1:36 PM
$1.00 on $ABBV here! 47% return!
0 · Reply